In-Situ Vaccination Using Sting Agonists Combined With Immune-Modulating Antibodies To Treat Lymphoma

We have developed a therapeutic “in situ vaccination” strategy against lymphomas involving the intratumoral injection of a STING agonist. The advantage of this approach is that it does not require the isolation of tumor specific antigens since the STING agonist will prim the immune system at the tumor site, where it can utilize endogenous tumor antigens.